JNJ240927C148000
- 18.50
- 0.000.00%
Johnson & Johnson Newsroom
J&J Needs to End Talc Lawsuits. The Third Time Could Be the Charm. -- Barrons.com
Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target
Johnson & Johnson Analyst Ratings
Johnson & Johnson Marks 50 Years In Singapore With Range Of Events
Novartis' Pluvicto Expected to Dominate Prostate Cancer Radiopharmaceutical Market
Is Johnson & Johnson (JNJ) the Best Future Stock For The Long-Term?
Express News | Johnson & Johnson subsidiary applies for bankruptcy protection due to talcum powder-caused cancer issues.
Sanofi Sarclisa Combo Gains Approval as First-line Multiple Myeloma Treatment
Johnson & Johnson Boosts Talc Settlement Payment to $8 Billion in Unit's Bankruptcy Case
Johnson & Johnson Files Third Bankruptcy Case Seeking to End Talc Lawsuits -- WSJ
Express News | Johnson & Johnson Shares Lose Ground Very Slightly, Last Down 0.6%
Express News | johnson & johnson (JNJ): In the baby powder cancer case, 83% of the plaintiffs support the company's proposed bankruptcy reorganization plan. The settlement costs have been further increased to over 8 billion US dollars.
Express News | J&J: Contemplated Settlement Represents Present Value of About $8 Bln to Be Paid Over 25 Years, Totaling About $10 Billion Nominal
Express News | J&J: Company Reiterates That None of Talc-Related Claims Against It Have Merit
Express News | J&J: Plan Would Resolve 99.75% of All Pending Talc Lawsuits Against Johnson & Johnson and Its Affiliates in the United States
Express News | J&J -Approximately 83% of Current Claimants and the Future Claims Representative Support the Proposed Bankruptcy Plan
Express News | J&J - Red River Increased Its Settlement Commitment by $1.75 Billion to Approximately $8 Billion
Express News | Johnson & Johnson Announces That Its Subsidiary, Red River Talc LLC, Has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
Sword of Justice! The US FTC sues three major pharmaceutical "middlemen", vows to correct the distorted profit chain.
The USA's FTC announced on its official website that it has filed a lawsuit against three major "pharmacy benefit managers" and their affiliated organizations, accusing them of engaging in anti-competitive and unfair kickback practices. FTC also "clearly stated" in the declaration its deep concern about the roles played by eli lilly and co, novo-nordisk a/s, sanofi, and other insulin pharmaceutical companies, and the competition bureau may recommend prosecuting these pharmaceutical companies in future enforcement actions.
Johnson & Johnson Myeloma Treatment Gets Approval Recommendation in Europe